COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab.

Bruchfeld, Annette; Kronbichler, Andreas; Alberici, Federico; Fervenza, Fernando C; Jayne, David RW; Segelmark, Mårten; Tesar, Vladimir; Szpirt, Wladimir M

View / Open Files

Published version (PDF, 320Kb)

Authors

Bruchfeld, Annette

Kronbichler, Andreas

Alberici, Federico

Fervenza, Fernando C

Jayne, David RW

Segelmark, Mårten

Tesar, Vladimir

Publication Date

2021-08-27

Journal Title

Nephrol Dial Transplant

ISSN

0931-0509

Publisher

Oxford University Press (OUP)

Volume

Issue

Pages

1758-1760

Language

eng

Type

Article

This Version

VoR

Physical Medium

Metadata

Show full item record

Citation

Bruchfeld, A., Kronbichler, A., Alberici, F., Fervenza, F. C., Jayne, D. R., Segelmark, M., Tesar, V., & et al. (2021). COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab.. Nephrol Dial Transplant, 36 (9), 1758-1760. https://doi.org/10.1093/ndt/gfab174

Abstract

COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.

Keywords

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Antineutrophil Cytoplasmic, COVID-19, COVID-19 Vaccines, Humans, Immunologic Factors, Remission Induction, Rituximab

Identifiers

External DOI: https://doi.org/10.1093/ndt/gfab174

This record's URL: https://www.repository.cam.ac.uk/handle/1810/330719

Rights

Attribution-NonCommercial 4.0 International

Licence URL: https://creativecommons.org/licenses/by-nc/4.0/

Statistics

Total file downloads (since January 2020). For more information on metrics see the IRUS guide.

Except where otherwise noted, this item's licence is described as Attribution-NonCommercial 4.0 International